Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:07:07 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:ANAB from 2023-05-04 to 2024-05-03 - 17 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-24 09:00U:ANABNews ReleaseActym Therapeutics Appoints Thomas Smart as CEO
2024-03-11 16:15U:ANABNews ReleaseAnaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-29 09:15U:ANABNews ReleaseAnaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting
2024-01-31 09:15U:ANABNews ReleaseAnaptys to Present at Guggenheim ¢ € ™s 6th Annual Biotechnology Conference
2023-11-27 16:15U:ANABNews ReleaseAnaptys Expands Immune Cell Modulator Pipeline with Exclusive License to ‚  BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
2023-11-07 16:15U:ANABNews ReleaseAnaptys Named a BioSpace 2024 Best Places to Work Winner
2023-11-02 16:15U:ANABNews ReleaseAnaptys Announces Third Quarter 2023 Financial Results and Provides ‚  Business Update
2023-11-01 09:15U:ANABNews ReleaseAnaptys Announces Participation in November Investor Conferences
2023-10-11 09:15U:ANABNews ReleaseAnaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
2023-10-09 08:15U:ANABNews ReleaseAnaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
2023-10-09 08:00U:ANABNews ReleaseAnaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
2023-09-18 16:15U:ANABNews ReleaseAnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
2023-09-12 09:15U:ANABNews ReleaseAnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
2023-08-07 16:15U:ANABNews ReleaseAnaptysBio Announces Second Quarter 2023 Financial Results ‚  and Provides Business Update
2023-07-31 13:35U:ANABNews ReleaseAnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
2023-05-30 16:15U:ANABNews ReleaseAnaptysBio Announces Participation in Upcoming Investor Conferences
2023-05-11 16:15U:ANABNews ReleaseAnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update